Literature DB >> 21678921

Biochemical characterization of human SET and MYND domain-containing protein 2 methyltransferase.

Jiaquan Wu1, Tony Cheung, Christie Grande, Andrew D Ferguson, Xiahui Zhu, Kelly Theriault, Erin Code, Cynthia Birr, Nick Keen, Huawei Chen.   

Abstract

SET and MYND domain-containing protein 2 (SMYD2) is a protein lysine methyltransferase that catalyzes the transfer of methyl groups from S-adenosylmethionine (AdoMet) to acceptor lysine residues on histones and other proteins. To understand the kinetic mechanism and the function of individual domains, human SMYD2 was overexpressed, purified, and characterized. Substrate specificity and product analysis studies established SMYD2 as a monomethyltransferase that prefers nonmethylated p53 peptide substrate. Steady-state kinetic and product inhibition studies showed that SMYD2 operates via a rapid equilibrium random Bi Bi mechanism at a rate of 0.048 ± 0.001 s(-1), with K(M)s for AdoMet and the p53 peptide of 0.031 ± 0.01 μM and 0.68 ± 0.22 μM, respectively. Metal analyses revealed that SMYD2 contains three tightly bound zinc ions that are important for maintaining the structural integrity and catalytic activity of SMYD2. Catalytic activity was also shown to be dependent on the GxG motif in the S-sequence of the split SET domain, as a G18A/G20A double mutant and a sequence deletion within the conserved motif impaired AdoMet binding and significantly decreased enzymatic activity. The functional importance of other SMYD2 domains including the MYND domain, the cysteine-rich post-SET domain, and the C-terminal domain (CTD), were also investigated. Taken together, these results demonstrated the functional importance of distinct domains in the SMYD family of proteins and further advanced our understanding of the catalytic mechanism of this family.
© 2011 American Chemical Society

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21678921     DOI: 10.1021/bi200725p

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  23 in total

1.  Using 'biased-privileged' scaffolds to identify lysine methyltransferase inhibitors.

Authors:  Sudhir Kashyap; Joel Sandler; Ulf Peters; Eduardo J Martinez; Tarun M Kapoor
Journal:  Bioorg Med Chem       Date:  2014-02-28       Impact factor: 3.641

2.  Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication.

Authors:  Ana Sílvia Pires-Luís; Márcia Vieira-Coimbra; Filipa Quintela Vieira; Pedro Costa-Pinheiro; Rui Silva-Santos; Paula C Dias; Luís Antunes; Francisco Lobo; Jorge Oliveira; Céline S Gonçalves; Bruno M Costa; Rui Henrique; Carmen Jerónimo
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

3.  Histone methyltransferase Smyd1 regulates mitochondrial energetics in the heart.

Authors:  Junco S Warren; Christopher M Tracy; Mickey R Miller; Aman Makaju; Marta W Szulik; Shin-Ichi Oka; Tatiana N Yuzyuk; James E Cox; Anil Kumar; Bucky K Lozier; Li Wang; June García Llana; Amira D Sabry; Keiko M Cawley; Dane W Barton; Yong Hwan Han; Sihem Boudina; Oliver Fiehn; Haley O Tucker; Alexey V Zaitsev; Sarah Franklin
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-30       Impact factor: 11.205

4.  Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2.

Authors:  Ramzi F Sweis; Zhi Wang; Mikkel Algire; Cheryl H Arrowsmith; Peter J Brown; Gary G Chiang; Jun Guo; Clarissa G Jakob; Steven Kennedy; Fengling Li; David Maag; Bailin Shaw; Nirupama B Soni; Masoud Vedadi; William N Pappano
Journal:  ACS Med Chem Lett       Date:  2015-04-29       Impact factor: 4.345

Review 5.  Cancer epigenetics drug discovery and development: the challenge of hitting the mark.

Authors:  Robert M Campbell; Peter J Tummino
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

6.  SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency.

Authors:  Daniela Boehm; Mark Jeng; Gregory Camus; Andrea Gramatica; Roland Schwarzer; Jeffrey R Johnson; Philip A Hull; Mauricio Montano; Naoki Sakane; Sara Pagans; Robert Godin; Steven G Deeks; Nevan J Krogan; Warner C Greene; Melanie Ott
Journal:  Cell Host Microbe       Date:  2017-05-10       Impact factor: 21.023

7.  Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.

Authors:  Linda Xiaoyan Li; Lucy X Fan; Julie Xia Zhou; Jared J Grantham; James P Calvet; Julien Sage; Xiaogang Li
Journal:  J Clin Invest       Date:  2017-06-12       Impact factor: 14.808

8.  Kinetic isotope effects reveal early transition state of protein lysine methyltransferase SET8.

Authors:  Joshua A Linscott; Kanishk Kapilashrami; Zhen Wang; Chamara Senevirathne; Ian R Bothwell; Gil Blum; Minkui Luo
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-09       Impact factor: 11.205

Review 9.  Protein and nucleic acid methylating enzymes: mechanisms and regulation.

Authors:  Daniel D Le; Danica Galonić Fujimori
Journal:  Curr Opin Chem Biol       Date:  2012-10-19       Impact factor: 8.822

10.  LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.

Authors:  Hannah Nguyen; Abdellah Allali-Hassani; Stephen Antonysamy; Shawn Chang; Lisa Hong Chen; Carmen Curtis; Spencer Emtage; Li Fan; Tarun Gheyi; Fengling Li; Shichong Liu; Joseph R Martin; David Mendel; Jonathan B Olsen; Laura Pelletier; Tatiana Shatseva; Song Wu; Feiyu Fred Zhang; Cheryl H Arrowsmith; Peter J Brown; Robert M Campbell; Benjamin A Garcia; Dalia Barsyte-Lovejoy; Mary Mader; Masoud Vedadi
Journal:  J Biol Chem       Date:  2015-03-30       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.